Loading data for RPRX — first visit, this takes a few seconds.
Royalty Pharma (RPRX)
NasdaqGS: RPRX
· Real-Time Price · USD
61.33
+0.02 (0.03%)
At close: Aug 26, 2026, 3:12 PM
The price, the headline numbers and the latest news, in one place.
Royalty Pharma (RPRX) Stock Price, Analysis & Data
0.03% (1D)
No data available
| Bid | 56.47 |
| Market Cap | 35.8B |
| Revenue (ttm) | 2.54B |
| Net Income (ttm) | 811.99M |
| 0.42 | |
| 1.86 | |
| 33.31 | |
| 10.8 | |
| P/B (ttm) | 4.04 |
| P/S (ttm) | 14.12 |
| Earnings Date | Nov 4, 2026 |
| Ask | 66.24 |
| Volume | 2,346,651 |
| Avg. Volume (20D) | 3,462,624 |
| Open | 61.12 |
| Previous Close | 61.31 |
| Day's Range | 60.80 - 61.54 |
| 52-Week Range | 34.08 - 62.13 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $0.94 (1.51%) |
| Ex-Dividend Date | Aug 14, 2026 |
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development fundi...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 2020
Employees 100
Stock Exchange NasdaqGS
Ticker Symbol RPRX
Website https://www.royaltypharma.com
Financial Performance
In 2025, Royalty Pharma's revenue was 2.38B, an increase of 5.06% compared to the previous year's 2.26B. Earnings were 770.95M, a decrease of -10.25%.
Financial StatementsEarnings Surprise
Royalty Pharma has released their quarterly earnings on Aug 5, 2026:
- Revenue of $674.14M misses estimates by $0, with 16.50% YoY growth.
- EPS of 1.32 exceeds estimates by 0.05, with 15.79% YoY growth.
Royalty Pharma is scheduled to release its earnings on Nov 4, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2